Search
Back

Cabazitaxel

CAS 1402820-62-5
Cabazitaxel

General Information

Derived from needles of yew trees, cabazitaxel is prescribed for the treatment of patients with hormone-refractory prostate cancer (HRPC) that has spread to other parts of the body and was previously treated with a docetaxel-containing treatment regimen. It is used in combination with prednisone. HRPC is a prostate cancer that has become unresponsive to hormonal manipulation.Cabazitaxel is administered intravenously.


About the API

Technology Synthetic
Therapeutic category Oncology
Systematic Name (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tertbutoxycarbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate – propan-2-one (1
Available formulations Injectables
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.